AEON Biopharma, Inc (AEON) Files For Up to $75M IPO

AEON Biopharma, Inc (NASDAQ: AEON) files for up to $75,000,000 IPO.

The company describes itself as: "We are a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. We plan to develop ABP-450 to address the estimated $2.2 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus, Inc., or Evolus, under the name Jeuveau. ABP-450 is manufactured by Daewoong Pharmaceuticals Co., Ltd., or Daewoong, in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by FDA, Health Canada and EMA to manufacture Jeuveau in the United States and Nuceiva in Canada and the European Union. We have exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. We have built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. "

Wells Fargo Securities, Cantor and Mizuho Securities and H.C. Wainwright & Co will serve as lead underwriters.

You May Also Be Interested In

• AEON Biopharma prices $13.75M public offering with milestone warrants
• SkinMedica launches advisory board and expands R&D lab in Irvine
• Research Alliance Corporation IV prices $75M IPO on Nasdaq